Latest Biotech News

Qiagen is reportedly assessing strategic options, including a potential sale, according to a Bloomberg report that sent shares higher. The life‑science tools and diagnostics provider has held...

A Phase I study reported that natural killer (NK) cell infusions produced promising signals in patients with recurrent hepatocellular carcinoma after liver transplantation. Investigators led by...

Worldwide Clinical Trials, a Kohlberg‑backed contract research organization, agreed to acquire Catalyst Clinical Research, a private CRO with oncology expertise. The deal is another example of...

Biotech investor Cormorant Capital raised $150 million to back another blank‑check merger as SPAC activity rebounds in life sciences. The firm, known for prior crossover SPAC deals with Moonlake...

Corxel Pharmaceuticals closed a $287 million Series D1 round to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...

Genmab halted patient enrollment in a Phase 1/2 trial of GEN1286, a cancer candidate acquired through its $1.8 billion purchase of ProfoundBio. The pause affects a study originally planned to...

Cigna’s Express Scripts is reportedly in discussions to settle claims by the Federal Trade Commission that pharmacy benefit managers steered patients to higher‑priced insulin to capture rebates....

Qiagen is reported to be evaluating strategic options, including possible sale discussions with multiple potential buyers, according to market reports. The life‑science tools and diagnostics...

Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research in a deal that continues private‑equity‑backed consolidation among contract research organizations (CROs). The acquisition...

Researchers published a next‑generation CAR‑T design that selectively leverages tumor features and microenvironmental cues to improve therapeutic specificity and efficacy. The study outlines...

A Nature Communications paper described a Granzyme B‑mimetic nanozyme packaged in targeted nanovesicles that induces apoptosis in cancer cells. The nanozyme architecture mimics the protease...

The SPARK multi‑cohort Phase II trial reported activity for the combination of sitravatinib and tislelizumab in locally recurrent or metastatic triple‑negative breast cancer (TNBC). The single‑arm...

A Phase I trial tested allogeneic natural killer (NK) cell infusions in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation and reported signals of safety and...

AnswersNow closed a $40 million Series B led by HealthQuest Capital to expand access to autism therapy via its digital platform. The funding will support scaling clinician networks, technology...

Lead: The multicohort SPARK phase II study reported tumor responses from the combination of sitravatinib and tislelizumab in patients with locally recurrent or metastatic triple-negative breast...

Lead: A phase I study evaluating adoptive natural killer (NK) cell infusions for recurrent hepatocellular carcinoma (HCC) after liver transplantation reported tolerability and preliminary...

Lead: Researchers disclosed a next‑generation CAR‑T engineering approach that programs T cells to sense and exploit tumor-specific features rather than relying solely on single-antigen...

Lead: A Nature Communications study introduced a Granzyme B‑mimetic nanozyme delivered in engineered nanovesicles that selectively induces apoptosis in cancer cells in preclinical models. Authors...

Lead: Two complementary reports from Ma et al. used transcriptome‑wide association study (TWAS) methods to nominate novel causal genes linked to diabetic nephropathy, expanding the genetic map of...

Lead: Bloomberg reported that Qiagen is evaluating strategic options, including a potential sale, after talks with multiple potential buyers and advisers. Market analysts and sources cited renewed...